CD4 and neoplasm: revealed the presence of immunostimulatory apCAFs in non-small-cell lung cancer (NSCLC), which activated and promoted survival of anti-tumor CD4+ effector T cells (17), which was highlighted by Dr. Anna Dart, the editor of Nature Reviews Cancer.